

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND  
CHANGE OF CORRESPONDENCE ADDRESS**

I hereby appoint:

☒ Practitioners at Customer Number: **52286** as my/our attorney(s) or agent(s) to prosecute the applications identified in the attached Table A, and to transact all business in the United States Patent and Trademark Office connected with said applications.

Address all telephone calls and correspondence to:

**Paul K. Legaard, Ph.D.  
Cozen O'Connor  
1900 Market Street  
Philadelphia, PA 19103  
Tel: 215-665-6914**

I am the:

☐ Applicant/Inventor.  
☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

**Signature of Applicant or Assignee of Record**

Respectfully submitted,  
National Research Council

Date: 20 April 2006

By: Marielle Piché  
Name: Marielle Piché  
Title: Secretary General

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant, National Research Council of Canada, a corporation of Canada, states that it is:

☒ the assignee of the entire right, title, and interest of the patents/applications identified in Table A attached hereto.

The extent (by, percentage) of its ownership interest is **100%** in the patents/applications identified in Table A.

☒ a copy of the pertinent assignment from the inventor(s) of the patent applications identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,  
National Research Council

Date: 20 April 2006

By: Marielle Piché  
Name: Marielle Piché  
Title: Secretary General

TABLE A

Docket Nos.	Application No/Patent No.	Filing Date/Issue Date	Examiner/Group Art Unit	Title
ASZN0038-100 A1573-1PUS	6,562,945	May 13, 2003	S. Gucker/1647	Galanin Receptor
ASZN0038-101 A1573-2P US	10/359,285	February 6, 2003	To Be Determined/To Be Determined	Novel Galanin Receptor
ASZN0039-100 A1807-1P US	6,696,257	February 24, 2004	J. Murphy/1646	G-Protein-Coupled Receptors From the Rat and Human (as amended)
ASZN0039-101 A1807-2P US	10/747,702	December 30, 2003	R. Li/1646	Novel G Protein-Coupled Receptor

ASSIGNMENT TO ASTRA PHARMA Inc

**Title:** NOVEL G PROTEIN-COUPLED RECEPTOR  
**Inventors:** Sultan Ahmad, Denis Banville, Yves Fortin, Paola  
Lembo, Dajan O'Donnell and Shi-Hsiang Shen  
**U.S. Appl. No:**  
**U.S. Filing Date:**  
**Execution Date of Application:**

As a below-named inventor, I hereby declare that:

My post office address is as stated below under my signature and I am named as inventor of the inventions or discoveries (herein INVENTIONS) as described in the patent application (herein APPLICATION) identified above. In view of valuable consideration, receipt thereof is hereby acknowledged, I do hereby assign and transfer unto ASTRA Pharma Inc., a corporation of Canada having a place of business at 1004 Middlegate Road, Mississauga, Ontario L4Y 1M4, Canada, its successors and assigns, my entire interest in and the full and exclusive right to the INVENTIONS, the APPLICATION and all related applications (including all divisions, reissues, continuations, and extensions thereof) and all counterparts in other countries, and any and all Letters Patent (and certificates of invention or similar certificates) (herein PATENTS) which may be granted based upon the INVENTIONS or the APPLICATION or related applications or counterparts in other countries; said transfer and assignment being applicable throughout the world. I hereby authorize and request officials of patent offices in any and all countries of the world to issue any and all of the PATENTS, when granted, to ASTRA Pharma Inc., its successors and assigns, as the assignee of my entire right, title, and interest in and to the same. I agree that I will communicate to ASTRA Pharma Inc., or its representatives, any facts known to me respecting the invention; testify in any legal proceedings; sign all lawful papers; execute all divisional, continuation, substitution, renewal, and reissue applications; execute all necessary assignment papers to cause any and all of the PATENTS to be issued to ASTRA Pharma Inc.; make all rightful oaths; and generally do everything possible to aid ASTRA Pharma Inc., its successors and assigns, to obtain and enforce proper protection for the INVENTION in any and all countries throughout the world.

FULL NAME OF FIRST/SOLE INVENTOR: Sultan Ahmad

Signature of Inventor: 

Address: Astra Research Centre Montreal, 7171 Fredrick-Banting, St Laurent, Quebec H4S 1Z9, Canada

Date: Mar 16/99

FULL NAME OF SECOND/JOINT INVENTOR: Denis Barville

Signature of Inventor: 

Address: 595 Lajeunesse, Ste-Dorothee, Quebec H7X 3K4, Canada

Date: 10/3/99


FULL NAME OF THIRD/JOINT INVENTOR: Yves Fortin

Signature of Inventor: 

Address: 2985 Avenue Douglas, Montreal, Quebec H3R 2E2, Canada

Date: 16 mars 1999

FULL NAME OF FOURTH/JOINT INVENTOR: Paola Lembo

Signature of Inventor: 

Address: Astra Research Centre Montreal, 7171 Fredrick-Banting, St Laurent, Quebec H4S 1Z9, Canada

Date: March 15, 99


FULL NAME OF FIFTH/JOINT INVENTOR: Dajan O'Donnell

Signature of Inventor: Dajan O'Donnell

Address: Astra Research Centre Montreal, 7171 Fredrick-Banting, St Laurent, Quebec H4S 1Z9, Canada

Date: March 16<sup>th</sup> 1999

FULL NAME OF SIXTH/JOINT INVENTOR: Shi-Hsiang Shen

Signature of Inventor: 

Address: 161 Charwell Crescent, Beaconsfield, Quebec H9W 1C2, Canada

Date: March 23, 1999

) ) ) ) ) ) )


) )

) ) )


)

Figure 1 is a line graph showing the effect of the concentration of the inhibitor on the rate of polymerization. The y-axis is labeled "Rate of polymerization" and ranges from 0 to 1.0. The x-axis is labeled "Concentration of inhibitor" and ranges from 0 to 1.0. The curve starts at (0, 1.0) and decreases as the concentration of inhibitor increases, approaching zero as the concentration approaches 1.0.


100

  
A Notary Public in and for  
the Province of Ontario

I **ANTHONY JANION GIBBS** of Wilmslow, Cheshire, England, Notary Public duly authorised admitted and sworn and practising within the United Kingdom of Great Britain and Northern Ireland **do hereby certify** that the photostat matter hereto annexed is a true copy of a document the original of which was produced to me at Macclesfield, Cheshire, England, this 22<sup>nd</sup> day of June in the year two thousand.



.....  
**Anthony Janion Gibbs**  
Notary Public





# CERTIFICATE

This is to certify that those  
articles are effective on

DECEMBER 31

# CERTIFICAT

Ceci certifie que les présents  
statuts entrent en vigueur le

DÉCEMBRE, 1999

**77196**

1.

Ant D. Lin

Director / Directeur  
Business Corporations Act / Loi sur les sociétés par actions

**Form 3  
Business  
Corporations  
Act**

**Formule 3**  
**Loi sur les**  
**sociétés par**  
**actions**

**ARTICLES OF AMENDMENT  
STATUTS DE MODIFICATION**

1. The name of the corporation is: \_\_\_\_\_

**Dénomination sociale de la société:**

ASTRA PHARMA INC.

2. The name of the corporation is changed to (if applicable):

**Nouvelle dénomination sociale de la société (s'il y a lieu):**

ASTRAZENZA CANADA INC.

3. Date of incorporation/amalgamation:

**Date de la constitution ou de la fusion:**

1954 JUNE 28

(Year, Month, Day)  
(année, mois, jour)

4. The articles of the corporation are amended as follows:

**Les statuts de la société sont modifiés de la façon suivante.**

To change the name of the Corporation to:

**ASTRAZENECA CANADA INC.**

5. The amendment has been duly authorized as required by Sections 168 & 170 (as applicable) of the Business Corporations Act.

*La modification a été dûment autorisée conformément aux articles 168 et 170 (selon le cas) de la Loi sur les sociétés par actions.*

6. The resolution authorizing the amendment was approved by the shareholders/directors (as applicable) of the corporation on

*Les actionnaires ou les administrateurs (selon le cas) de la société ont approuvé la résolution autorisant la modification le*

**1999 DECEMBER 22**

(Year, Month, Day)  
(année, mois, jour)

These articles are signed in duplicate.

*Les présents statuts sont signés en double exemplaire.*

**ASTRA PHARMA INC.**

(Name of Corporation)  
(Dénomination sociale de la société)

By:/Par:

(Signature)  
(Signature)

(Description of Office)  
(Fonction)

**List of Applications on Which the Name of the Assignee Should Be  
Changed from Astra Pharma Inc. to AstraZeneca Canada Inc.**

09/254,227

09/341,016

09/554,326

09/029,633

09/555,576

09/555,579

09/555,580

09/555,575

09/029,468

08/836,830

09/460,722

09/460,723

08/981,700

## Assignment to the National Research Council of Canada

Applicant(s): Ahmad, *et al.*  
Appl. No.: 09/254,227  
Filed: March 3, 1999  
For: **G Protein-Coupled Receptors from the Rat and Human** (as amended)


AstraZeneca Canada Inc., a corporation of Canada, having a place of business at 1004 Middlegate Road, Mississauga, Ontario, L4Y 1M4, Canada (hereinafter "AstraZeneca Canada") is owner of right, title and interest in the inventions and discoveries (hereinafter "Inventions") described in the above-identified United States application (hereinafter "Application") by virtue of an Assignment executed by the inventors and recorded in the United States Patent and Trademark Office on January 19, 2000 at Reel 10414, Frame 0583, and a merger document recorded in the United States Patent and Trademark Office on October 12, 2000 at Reel 011217, Frame 0591.

In view of valuable consideration, receipt of which is hereby acknowledged, AstraZeneca Canada hereby assigns and transfers unto the National Research Council of Canada (hereinafter "NRC"), an agency of the Government of Canada, located at 1200 Montreal Road, Bldg. M-58, Ottawa, Ontario, K1A 0R6, Canada, its successors and assigns, AstraZeneca Canada's entire right, title and interest in the Inventions, the Application and all related applications (including all divisions, reissues, continuations, and extensions thereof) and all counterparts in other countries, and any and all Letters Patent (and certificates of invention or similar certificates) (hereinafter "Patents") which may be granted based upon the Inventions or the Application or related applications or counterparts in other countries, said transfer and assignment being applicable throughout the world. AstraZeneca Canada authorizes and requests officials of patent offices in any and all countries of the world to issue

any and all of the Patents, when granted, to NRC, its successors and assigns, as the assignee of AstraZeneca Canada's entire right, title, and interest in and to the same.

ASTRAZENECA CANADA INC.

Date 27 Sept 2003

By   
Bo Hasslev  
Director IP Finance and IS